Purine and Pyrimidine Metabolism
On this page
Direct answer
Purine rings are assembled atom by atom directly onto ribose phosphate, whereas pyrimidines are built first as a free ring (orotate) and only then attached to ribose — the architectural difference examiners test first. Both pathways begin from 5-phosphoribosyl-1-pyrophosphate (PRPP), made by PRPP synthetase. Amidophosphoribosyl transferase, the committed and rate-limiting enzyme of purine synthesis, is feedback-inhibited by AMP and GMP; cytosolic carbamoyl phosphate synthetase II holds the same position for pyrimidines, inhibited by UTP and activated by ATP (the mitochondrial CPS I belongs to the urea cycle instead). Salvage pathways recycle free bases through hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase. Purine catabolism ends in insoluble uric acid; pyrimidines degrade to soluble beta-alanine and beta-aminoisobutyrate, which is why only purines form stones and gout.
What you must remember
- Atom sources for purines: glycine (C4, C5, N7), glutamine (N2, N9), aspartate (N1, N6), two formyl-folate one-carbon units (C2, C8) and carbon dioxide (C6) — a standard "identify the labelled atom" question.
- Key purine intermediates and regulation: PRPP synthetase and amidophosphoribosyl transferase (inhibited by AMP, GMP; activated by PRPP); IMP is the branch point to AMP (adenylosuccinate synthetase) and GMP (IMP dehydrogenase, inhibited by mycophenolate).
- Pyrimidine specifics: carbamoyl phosphate synthetase II (cytosolic, UTP-inhibited, ATP-activated) heads a trifunctional CAD enzyme that also carries aspartate transcarbamoylase and dihydroorotase activities; UMP is the first pyrimidine nucleotide made.
- Salvage enzymes: HGPRT (hypoxanthine and guanine) and APRT (adenine), both PRPP-dependent; thymidine kinase salvages thymidine and is a viral-drug activation site for aciclovir.
- Catabolic ends: purines to hypoxanthine, xanthine and finally uric acid by xanthine oxidase — inhibited by allopurinol (converted to oxypurinol, suicide substrate) and febuxostat; pyrimidines to beta-alanine (from uracil, cytosine) and beta-aminoisobutyrate (from thymine).
- Clinical blocks: gout from urate excess; Lesch-Nyhan from HGPRT absence; adenosine deaminase deficiency causing SCID (the first gene-therapy target); hereditary orotic aciduria from UMP synthase deficiency with megaloblastic anaemia refractory to B12 and folate, treated with uridine.
- Antimetabolite logic: methotrexate blocks thymidylate synthesis (dihydrofolate reductase), 5-fluorouracil blocks thymidylate synthase, 6-mercaptopurine is a purine analogue — each exploits a pathway step.
How to work through a hyperuricaemia case
A 45-year-old obese man on thiazide and low-dose aspirin wakes with an exquisitely painful first metatarsophalangeal joint; aspirate shows needle-shaped, strongly negative birefringent crystals. Build the logic in three questions. Is production excessive or excretion poor? Here drugs reduce renal urate clearance, the commonest mechanism in Indian clinic practice, while Lesch-Nyhan and PRPP synthetase superactivity are the rare overproduction models. Is it uric acid or something else? Xanthine oxidase deficiency gives hypouricaemia with xanthine stones, and tumour lysis releases massive purine loads treatable with rasburicase, which enzymatically degrades urate to allantoin. Which drug, which mechanism? Allopurinol is converted by xanthine oxidase itself into oxypurinol, which binds the enzyme tightly — a suicide-inhibition story examiners reward; febuxostat is the non-purine alternative.
Contrast a child with hereditary orotic aciduria: megaloblastic anaemia failing B12 and folate, growth retardation and orotate crystals in urine, with normal blood ammonia and no urea-cycle confusion because CPS II, not CPS I, is cytosolic. Uidine bypasses the block and replenishes pyrimidine pools, one of the few single-nucleotide prescriptions in medicine.
Where students slip
The CPS I versus CPS II confusion costs a whole question: mitochondrial CPS I uses ammonia and N-acetylglutamate for urea; cytosolic CPS II uses glutamine and is inhibited by UTP — linking orotic acid to ammonia levels wrongly mixes the two. Second, students place PRPP as an inhibitor of purine synthesis unconditionally; PRPP activates amidophosphoribosyl transferase while its products AMP and GMP inhibit it, and excess PRPP in HGPRT deficiency drives overproduction, not suppression. Third, uric acid's low solubility (uricase is absent in humans) is the reason for gout and for the tumour-lysis threat, not merely "high levels". Finally, remember orotic aciduria does not raise ammonia, the discriminator from urea-cycle defects.
Frequently asked questions
What distinguishes purine from pyrimidine ring synthesis?
Purines are built on ribose phosphate stepwise from PRPP, while the pyrimidine ring is assembled free as orotate and attached to PRPP afterwards.
Which are the rate-limiting enzymes of the two de novo pathways?
Amidophosphoribosyl transferase for purines and cytosolic carbamoyl phosphate synthetase II for pyrimidines, both feedback-inhibited by their end-product nucleotides.
Why is uric acid troublesome in humans?
Human lack of uricase leaves urate as the insoluble end product, so supersaturation deposits monosodium urate crystals in joints and stones in the urinary tract.
How does allopurinol reduce urate production?
Xanthine oxidase converts allopurinol to oxypurinol, which binds the reduced enzyme tightly (suicide inhibition), diverting purines to more soluble intermediates.
What characterises hereditary orotic aciduria?
UMP synthase (orotate phosphoribosyltransferase plus decarboxylase) deficiency causing megaloblastic anaemia unresponsive to B12 and folate, with orotate crystalluria and normal ammonia, treated with uridine.